1. Larger numbers of immature dendritic cells augment an anti-tumor effect against established murine melanoma cells
- Author
-
Young Hun Cho, Min Geol Lee, and Taehyung Lee
- Subjects
Cell Survival ,medicine.medical_treatment ,Cell Count ,Bioengineering ,Spleen ,Cell Communication ,Biology ,Applied Microbiology and Biotechnology ,Mice ,Immune system ,Cancer immunotherapy ,Cell Line, Tumor ,medicine ,Animals ,Melanoma ,Cell Proliferation ,Cell growth ,Dendritic Cells ,General Medicine ,Dendritic cell ,Immunotherapy ,Th1 Cells ,medicine.disease ,Mice, Inbred C57BL ,medicine.anatomical_structure ,Cell culture ,Immunology ,Cytokines ,Female ,Biotechnology - Abstract
The dendritic cell (DC) is a potentially promising tool for cancer immunotherapy. To date, however, DC-based immunotherapy has not yielded data with which firm conclusions can be drawn. In the present study, we tested the dose-dependant enhancement of the anti-tumor effect induced by DCs. When large numbers of DCs were used, tumor growth was suppressed up to 41% when compared to control mice. Survival of the animals was prolonged to 54 days compared to the 33-day survival the control mice. The delayed-type hypersensitivity (DTH) response induced was 26-fold higher than in the controls. Larger numbers of DCs also led to higher expansion of IFN-gamma-secreting-CD8(+) T cells. Furthermore, the secretion of IL-12p70 and IFN-gamma by spleen cells were enhanced in proportion to the dosage. However, the level of IL-4 secreted from spleen cells was negligible compared to the level of IFN-gamma that was released. These results indicate that DCs induce Th1-dominant immune response and that more DCs could lead to better immunological results, a finding which was consistent with our therapeutic results.
- Published
- 2006
- Full Text
- View/download PDF